



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Hangauer et al.
SERIAL NUMBER : 09/482,585 EXAMINER : P. Ponnaluri
FILING DATE : January 13, 2000 ART UNIT : 1639
FOR : A NOVEL METHOD FOR DESIGNING PROTEIN KINASE
INHIBITORS

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Information Disclosure Statement is being filed concurrently with the filing of a Request For Continued Examination under 37 C.F.R. §1.114. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Hangauer et al.
U.S.S.N.: 09/482,585

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 28856-501.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: May 17, 2005

TRA 2036034v1

Express Mail No.: EV 475171398 US

Date of Deposit: May 17, 2005

Page 1 of 2

Attorney Docket No.: 28856-501

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/482,585
	Filing Date	January 13, 2000
	First Named Inventor	Hangauer
	Group Art Unit	1639
	Examiner Name	P. Ponnaluri
	Attorney Docket Number	28856-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C17	Alfaro-Lopez et al. <i>J. Med. Chem.</i> , 41:2252-2260 (1998)
	C18	Burke et al. <i>J. Med. Chem.</i> , 36(4):425-432 (1993)
	C19	Choi "Development of a Cellular Mimetic Protein Kinase Assay and a Novel Methodology for Determining the Mode of Inhibition for Multisubstrate" thesis, Bell & Howell Co., (1999)
	C20	Faltynek et al. <i>Biochem.</i> , 34:12404-12410 (1995)
	C21	Fry et al. <i>Science</i> , 265:1093-1095 (1994)
	C22	Hanke et al. <i>J. Biol. Chem.</i> , 271(2):695-701 (1996)
	C23	Hsiao et al. <i>Synthesis</i> , pgs. 1043-1046 (1998)
	C24	Hubbard <i>EMBO J.</i> , 16(18):5572-5581 (1997)
	C25	Kim et al. <i>Int. J. Peptide Protein Res.</i> , 44:457-465 (1994)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C26	Lai et al. <i>J. Org. Chem.</i> , 61:1872-1874 (1996)
	C27	Lai et al. <i>J. Peptide Res.</i> , 51:271-281 (1998)
	C28	Levitzki et al. <i>Science</i> , 267:1782-1788 (1995)
	C29	Lou et al. <i>Bioorg. Med. Chem.</i> , 4(5):677-682 (1996)
	C30	Mohammadi et al. <i>Science</i> , 276:955-960 (1997)
	C31	Nair et al. <i>Synthesis</i> , pgs. 810-814 (1995)
	C32	Nair et al. <i>J. Med. Chem.</i> , 38:4276-4283 (1995)
	C33	Patrick et al. <i>DDT</i> , 1(8):325-330 (1996)
	C34	Ramdas et al. <i>Arch. Biochem. Biophys.</i> , 323(2):237-242 (1995)
	C35	Rewcastle et al. <i>J. Med. Chem.</i> , 39:1823-1835 (1996)
	C36	Saperstein et al. <i>Biochem.</i> , 28:5694-5701 (1989)
	C37	Sawutz et al. <i>Biochem. Pharmacol.</i> , 51:1631-1638 (1996)
	C38	Showalter et al. <i>Pharmacol. Ther.</i> , 76(1-3):55-71 (1997)
	C39	Thakkar et al. <i>J. Med. Chem.</i> , 36:2950-2955 (1993)
	C40	Xu et al. <i>Nature</i> , 385:595-602 (1997)
	C41	Zheng et al. <i>Biochem.</i> , 32:2154-2161 (1993)
	C42	Burke, et al. <i>Acc. Chem. Res.</i> , 36:426-433 (2003)
	C43	Johnson, et al., <i>Nature Reviews</i> , 1:696-709 (2002)
	C44	Levitzki, <i>Acc. Chem. Res.</i> , 36:462-469 (2003)
	C45	Pestell, et al. <i>Oncogene</i> , 19:6607-6612 (2000)
	C46	McCluskey, et al. <i>J. Med. Chem.</i> , 45:1151-1175 (2002)
	C47	Susa, et al., <i>TiPS</i> , 21:489-495 (2000)
	C48	Zhang, <i>Annu. Rev. Pharmacol. Toxicol.</i> , 42:209-234 (2002)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.